Cell and gene therapy 2018
EuroSciCon Conference on Cell and Gene Therapy 2018
Amsterdam, Netherlands
20 - 21 August 2018
The conference ended on 21 August 2018
Important Dates
Abstract Submission Deadline
20th July 2018
Early Bird Deadline
25th July 2018
About Cell and gene therapy 2018
The EuroSciCon will be holding the international Cell and Gene Therapy 2018 conference focusing on Advancements in Cell and Gene therapy, August 20-21,2018 in Amsterdam, Netherlands. The theme of this year’s meeting is “Advancements in Cell and Gene Therapy : Making a dead cell work" that will provide an international platform for discussion of present and future challenges in Cell and Gene therapy and expertise meeting. World-leading health practitioners, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and emerging research
Topics
Gene therapy, Molecular genetics, Regenerative medicine, Gene regulation and signalling;, Metabolism and gene expression microbial taxonomyCall for Papers
- Cell Science Research
- Cell & Gene Therapy
- Regenerative Medicine
- Immunotherapy
- Genetics And Stem Cell Biology
- Epigenetics
- Human Genomics
- Next Generation Sequencing
- Gene Editing And CRISPR Based Technologies
- Proteomics
- Viral Gene Therapy
- Cell Therapy Of Cardiovascular Disorders
- Regulatory And Safety Aspects Of Cell And Gene Therapy
- Markets & Future Prospects For Cell & Gene Therapy
- Plant Genetics
- Longetivity
- Gene Therapy For Diseases
- Stem Cell Therapy
- Gene Editing
- Vectors Used In Gene Therapy
- Cell Biology
- Ethical Issues Related To Gene Therapy
- Gene Therapy In Tissue Engineering
- Genomic Medicine
- Cell Culture Processes
- Cellular Pathology
- Cell Damage And Adaptation
- Nanotechnology In Stem Cells
Keep Up to Date with PaperCrowd
Sign up and follow your favorite conferences.
Add Admin
Add Website
Add Deadline
Add Deadline
← Back
Log In
← Back
Sign Up
Success! We've just sent you an email with your followers.